Cartesian Therapeutics, Inc.
RNAC· Nasdaq
RNACCartesian Therapeutics, Inc.
Filed Mar 2, 2023 · 10-K · 61 days after period end · 0001453687-23-000040
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $16.80M | $29.94M | $11.95M | $6.65M |
| Net Income | $5.89M | $12.24M | -$15.45M | -$14.89M |
| EPS Diluted | — | — |
Cartesian Therapeutics, Inc. · CIK 1453687 · Engraved from SEC EDGAR
| — |
| -$0.28 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 2, 2023 · 61 d after period end
